SCHUMACHER
16-08-2016, 12:40 PM
http://dimerix.com/
BOUGHT A FEW OF THESE TODAY as i like the story and their fast track approach - Bought at 1.3c - Currently at Phase 11 trials and had some successes to date read on... some good volume of late leading into trial results
http://www.aspectfinancial.com.au/docserver/01762833.pdf?fileid=01762833&datedir=20160729&edt=MjAxNi0wOC0xNisxMDo0NjoxNSsxMjArNjEyMDg3ODIrZX RyYWRleG1sK3JlZGlyZWN0Ky9pbWFnZXNpZ25hbC9lcnJvcnBh Z2VzL0V0cmFkZVBERlRpbWVvdXQuaHRtbCsvaW1hZ2VzaWduYW wvZXJyb3JwYWdlcy9wZGZkZWxheWVkLmpzcA==&popup=true
http://www.aspectfinancial.com.au/docserver/01761419.pdf?fileid=01761419&datedir=20160728&edt=MjAxNi0wOC0xNisxMDo0MTozNSsxMjArNjEyMDg3ODIrZX RyYWRleG1sK3JlZGlyZWN0Ky9pbWFnZXNpZ25hbC9lcnJvcnBh Z2VzL0V0cmFkZVBERlRpbWVvdXQuaHRtbCsvaW1hZ2VzaWduYW wvZXJyb3JwYWdlcy9wZGZkZWxheWVkLmpzcA==&popup=true
http://www.aspectfinancial.com.au/docserver/01763166.pdf?fileid=01763166&datedir=20160801&edt=MjAxNi0wOC0xNisxMDo0MjoyMSsxMjArNjEyMDg3ODIrZX RyYWRleG1sK3JlZGlyZWN0Ky9pbWFnZXNpZ25hbC9lcnJvcnBh Z2VzL0V0cmFkZVBERlRpbWVvdXQuaHRtbCsvaW1hZ2VzaWduYW wvZXJyb3JwYWdlcy9wZGZkZWxheWVkLmpzcA==&popup=true
Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA
KEY POINTS:
Path to drug registration in USA of DMX-200 in patients with chronic kidney disease (CKD)confirmed
Path to the near term milestone of filing IND for the first US study(PK study) –no apparent road blocks or
extra costs identified at this stage
DMX-200 to be treated as an adjunct therapy rather than a combination therapy–resultingin a much smaller
pivotal trial which is less expensive as it requires fewer patients
Potential for approval from asingle pivotal Phase IIItrialwith single end point of improvement in proteinuria
from baseline
–bringing huge cost benefits over running two
Phase III trials
Recognition of the importance of heterodimer pharmacology– validating the patented Dimerix technology in identifying new treatments
Who we are:
A clinical
-stage drug development company focused on commercialising new therapeutic treatments identified using our proprietary drug discovery platform.
Discovery Platform:
Receptor-HIT technology to identify clinical opportunities from drug-receptor interactions, and potential revenue generation.
Lead Program:
A therapy (DMX-200) currently in Phase II clinical trial for Chronic Kidney Disease (CKD) and US Orphan Drug Designation for Focal Segmental
Glomerulosclerosis (FSGS).
Leadership:
Commercially focused and experienced board and management with a record of hitting milestones and creating significant shareholder value.
Key Assets 3
•Pre IND meeting with FDA held 29th June 2016
•Therapeutic use patent granted in USA 19th April 2016
BOUGHT A FEW OF THESE TODAY as i like the story and their fast track approach - Bought at 1.3c - Currently at Phase 11 trials and had some successes to date read on... some good volume of late leading into trial results
http://www.aspectfinancial.com.au/docserver/01762833.pdf?fileid=01762833&datedir=20160729&edt=MjAxNi0wOC0xNisxMDo0NjoxNSsxMjArNjEyMDg3ODIrZX RyYWRleG1sK3JlZGlyZWN0Ky9pbWFnZXNpZ25hbC9lcnJvcnBh Z2VzL0V0cmFkZVBERlRpbWVvdXQuaHRtbCsvaW1hZ2VzaWduYW wvZXJyb3JwYWdlcy9wZGZkZWxheWVkLmpzcA==&popup=true
http://www.aspectfinancial.com.au/docserver/01761419.pdf?fileid=01761419&datedir=20160728&edt=MjAxNi0wOC0xNisxMDo0MTozNSsxMjArNjEyMDg3ODIrZX RyYWRleG1sK3JlZGlyZWN0Ky9pbWFnZXNpZ25hbC9lcnJvcnBh Z2VzL0V0cmFkZVBERlRpbWVvdXQuaHRtbCsvaW1hZ2VzaWduYW wvZXJyb3JwYWdlcy9wZGZkZWxheWVkLmpzcA==&popup=true
http://www.aspectfinancial.com.au/docserver/01763166.pdf?fileid=01763166&datedir=20160801&edt=MjAxNi0wOC0xNisxMDo0MjoyMSsxMjArNjEyMDg3ODIrZX RyYWRleG1sK3JlZGlyZWN0Ky9pbWFnZXNpZ25hbC9lcnJvcnBh Z2VzL0V0cmFkZVBERlRpbWVvdXQuaHRtbCsvaW1hZ2VzaWduYW wvZXJyb3JwYWdlcy9wZGZkZWxheWVkLmpzcA==&popup=true
Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA
KEY POINTS:
Path to drug registration in USA of DMX-200 in patients with chronic kidney disease (CKD)confirmed
Path to the near term milestone of filing IND for the first US study(PK study) –no apparent road blocks or
extra costs identified at this stage
DMX-200 to be treated as an adjunct therapy rather than a combination therapy–resultingin a much smaller
pivotal trial which is less expensive as it requires fewer patients
Potential for approval from asingle pivotal Phase IIItrialwith single end point of improvement in proteinuria
from baseline
–bringing huge cost benefits over running two
Phase III trials
Recognition of the importance of heterodimer pharmacology– validating the patented Dimerix technology in identifying new treatments
Who we are:
A clinical
-stage drug development company focused on commercialising new therapeutic treatments identified using our proprietary drug discovery platform.
Discovery Platform:
Receptor-HIT technology to identify clinical opportunities from drug-receptor interactions, and potential revenue generation.
Lead Program:
A therapy (DMX-200) currently in Phase II clinical trial for Chronic Kidney Disease (CKD) and US Orphan Drug Designation for Focal Segmental
Glomerulosclerosis (FSGS).
Leadership:
Commercially focused and experienced board and management with a record of hitting milestones and creating significant shareholder value.
Key Assets 3
•Pre IND meeting with FDA held 29th June 2016
•Therapeutic use patent granted in USA 19th April 2016